article · Journal of Contemporary Brachytherapy

Safety of high-dose-rate brachytherapy in patients with prostate cancer and inflammatory bowel disease: A case series

Horatio Thomas
Jie Jane Chen
Comron Hassanzadeh
Hasan Abdulbaki
I‐Chow Hsu
Oi Wai Chau
Nauman Malik
Alan Ayoub
Ali Sabbagh
Haitham Shaheen
Osama Mohamad

2024Open accessSuez Canal University

Abstract

HDR brachytherapy appears to be a safe and tolerable treatment modality for patients with prostate cancer and IBD, with minimal acute and late GI and GU toxicity. These findings warrant multi-institutional validation due to small sample size.

Research topics

Prostate Cancer Diagnosis and Treatment
Prostate Cancer Treatment and Research
Hepatocellular Carcinoma Treatment and Prognosis

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.5114/jcb.2024.135645

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.